2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
JBS N.V. submitted a non-binding proposal to Pilgrim's Pride's board to acquire all PPC shares it does not already own, in exchange for 2.086 JBS Class A shares per PPC share. JBS owns about 82% of PPC, and the filing says there is no guarantee a binding agreement will be reached. For PPC minority shareholders, the proposal would replace their PPC shares with JBS shares and end PPC's public listing if completed.
Exchange ratio of 2.086 JBS Class A shares per PPC share, based on August 18, 2026 closing prices of $13.66 for JBS and $28.49 for PPC
JBS currently owns approximately 82% of PPC common stock
Proposal requires approval by a special committee of independent directors and a majority of votes cast by unaffiliated PPC shares; it is not binding
If completed, PPC shares would stop trading on Nasdaq and be deregistered
Nasdaq notified Skye Bioscience on August 18, 2026 that its stockholders' equity of ($497,307), as reported in its June 30, 2026 quarterly report, falls short of the $2,500,000 minimum under Nasdaq Capital Market Listing Rule 5550(b)(1). The notice has no immediate effect on the listing, and the stock continues to trade as SKYE, but the company must submit a plan to regain compliance and says there is no assurance it will do so. The notice comes alongside a pending acquisition of Redx Pharma Limited, which adds uncertainty for shareholders.
Stockholders' equity was ($497,307) versus a $2,500,000 minimum under Nasdaq Listing Rule 5550(b)(1)
Stock continues to trade on the Nasdaq Capital Market under SKYE; the notice has no immediate effect on listing
Compliance plan due October 2, 2026; if accepted, Nasdaq can grant an extension to February 14, 2027
Company is evaluating alternatives and says there can be no assurance it will regain compliance; Redx transaction agreement is dated August 14, 2026
Sezzle and WebBank entered into amended bank program agreements on August 12, 2026, adding two products, SezzleCash and Sezzle Send, to the existing loan program. For those two products WebBank will keep loans on its balance sheet up to an initial $30.0 million threshold, which it may raise to $150.0 million, and Sezzle's minimum tangible net worth requirement rises from $12.0 million to $100.0 million.
Agreements dated August 12, 2026 amend and restate the September 26, 2024 bank program agreements with WebBank.
WebBank will retain SezzleCash and Sezzle Send loans to maturity, with an initial retention threshold of $30.0 million, which WebBank may raise up to $150.0 million.
Minimum tangible net worth covenant increases from $12.0 million to $100.0 million; new termination events added for judgments, fines or penalties and financial covenant breaches.
Program term is unchanged and runs through September 27, 2029; full agreements to be filed with the Form 10-Q for the quarter ending September 30, 2026.
AbbVie completed an underwritten offering of nine series of senior notes on August 18, 2026, totaling $10.0 billion in principal across floating rate notes maturing 2028 and fixed rate notes maturing 2028 through 2066. AbbVie expects to use the net proceeds to fund part of the cash consideration for its acquisition of Apogee Therapeutics and related fees, with any remainder for general corporate purposes.
Nine series of notes totaling $10.0 billion in aggregate principal, registered under AbbVie's Form S-3ASR dated February 14, 2025
Net proceeds to fund a portion of the cash consideration due to Apogee shareholders and related fees and expenses
If the Apogee acquisition is terminated or abandoned, AbbVie must redeem most series (not the 2056 or 2066 Notes) at 101% of principal plus accrued interest
Notes are unsecured and rank equally with AbbVie's existing and future unsecured, unsubordinated debt
Keysight reported preliminary third-quarter fiscal 2026 results for the period ended July 31, 2026, with revenue of $1.85 billion and GAAP net income of $397 million, or $2.30 per share, compared with $1.35 billion and $1.10 per share a year earlier. The company also expects fourth-quarter revenue of $1.930 billion to $1.950 billion and non-GAAP earnings of $3.34 to $3.40 per share.
Q3 revenue was $1.85 billion, up from $1.35 billion in the third quarter of 2025; orders were $2.09 billion.
GAAP diluted EPS was $2.30 versus $1.10 a year earlier; non-GAAP diluted EPS was $3.07 versus $1.72.
Fourth-quarter fiscal 2026 guidance: revenue of $1.930 billion to $1.950 billion and non-GAAP EPS of $3.34 to $3.40.
Free cash flow was $403 million in the quarter, compared with $291 million a year earlier.
Liminatus Pharma said it will carry out a 1-for-50 reverse stock split of its common stock, effective August 20, 2026, so its shares can meet Nasdaq's $1.00 minimum bid price. The company remains listed under a Nasdaq Panel exception, but it must show a $1.00 closing bid for at least ten consecutive trading days by September 3, 2026, and the company says it cannot assure it will do so.
Reverse split ratio of 1-for-50, with split-adjusted trading under LIMN on The Nasdaq Capital Market expected at the market open on August 21, 2026
New CUSIP number 53271X 207; fractional shares will be rounded up to the nearest whole share, with no cash paid for fractions
Based on July 2, 2026 figures, outstanding shares would fall from 67,160,362 to approximately 1,343,208
Nasdaq Panel extended the deadline to demonstrate compliance with Listing Rule 5550(a)(2) to September 3, 2026
On August 12, 2026, Singularity Future Technology amended its June 19, 2025 securities purchase agreement with eighteen investors and issued them 2,299,212 common shares under Regulation S. The amendment also commits the company to issue amended and restated warrants exercisable at $0.001 per share, and those warrants will not be issued until shareholder approval is obtained.
Issued 2,299,212 common shares to the Investors on August 12, 2026, on the post-1:14-reverse-split basis.
Original June 19, 2025 placement covered 32,188,841 units pre-split (2,299,212 post-split) for gross proceeds of approximately $30 million.
Amended and restated warrants would be exercisable at $0.001 per share, versus the original $16.310 post-split exercise price.
Amended warrant issuance requires shareholder approval; the filing does not state a date for that vote.
Diodes completed a private offering of $375 million of 0.00% convertible senior notes due August 15, 2031, including the full exercise of a $50.0 million option, and amended its senior credit agreement to extend the revolver maturity to August 12, 2031 and permit the new debt. The notes carry a conversion price of about $145.79 per share, a 50.0% premium to the $97.19 closing price on August 13, 2026, so the offering adds debt that may dilute shareholders if the stock rises above that level.
Offering of $375 million principal closed August 18, 2026, including $50.0 million from the full exercise of the initial purchasers' option
Notes mature August 15, 2031; no regular interest; conversion price about $145.79 per share
Net proceeds estimated at $364.6 million with the option exercised, after costs; $35.0 million used to repurchase about 0.36 million shares at $97.19
Credit agreement amendment, effective August 12, 2026, extends revolver maturity to August 12, 2031 and changes pricing and covenants
Mercury Systems reported fourth-quarter and fiscal 2026 results for the period ended July 3, 2026. Revenue grew, and bookings and backlog hit company records, but fourth-quarter GAAP net income fell to $1 million from $16 million a year earlier, and management said it is increasing its organic growth outlook without giving new figures.
Q4 fiscal 2026 revenue was $290 million, up from $273 million; bookings were $660 million, up 93.1%
Q4 GAAP diluted EPS was $0.01 versus $0.27 a year earlier; adjusted EBITDA was $49 million versus $51 million
Full-year revenue rose to $984 million from $912 million; GAAP net loss narrowed to $30 million ($0.50 per share) from $38 million
Backlog exceeded $1.9 billion, up 38.4% year over year; management said it is increasing its outlook for organic growth
Catalyst Bank entered into a new employment agreement with President and CEO Joseph B. Zanco on August 17, 2026, running through August 17, 2029. The filing sets a $350,000 base salary and includes enhanced severance and change-in-control terms, so shareholders should note the potential cost if his employment ends.
New agreement term runs August 17, 2026 to August 17, 2029, unless renewed or extended.
Base salary of $350,000, which the board may increase at its discretion.
Severance on involuntary termination: 12 months of base salary; 36 months if terminated within 30 days after a change in control.
Flexible Solutions International reported a second-quarter 2026 net loss of $1,912,967, or $0.15 per share, versus net income of $2,028,912, or $0.16 per share, a year earlier. Sales fell about 14% to $7,610,148, and management said scale-up costs for food-grade and Panama operations outweighed revenue so far, with the company expecting a return to profitability in Q3 2026.
Q2 2026 sales were $7,610,148, down about 14% from $8,867,132 in Q2 2025, which included a $2.5 million R&D payment not repeated in 2026.
Q2 2026 net loss was $1,912,967 ($0.15 per share), compared with net income of $2,028,912 ($0.16 per share) in Q2 2025.
Management guided that Panama revenue could reach $3 million, ENP revenue could exceed $5 million, and NanoChem revenue could exceed $4 million in Q3 2026.
Management expects to raise prices to customers in the third or fourth quarter unless oil prices fall significantly.
Rexford Industrial Realty agreed on August 13, 2026 to sell a portfolio of 22 industrial properties to an affiliate of EQT Real Estate for about $1.2 billion in cash, subject to customary closing adjustments. The sale is part of a previously announced $2.0 billion disposition program of non-core assets, and the company reaffirmed its 2026 guidance. Shareholders will watch whether the closing occurs by the expected September 30, 2026 date and how the net proceeds are used.
22 industrial properties, aggregate purchase price of about $1.2 billion payable in cash at closing
Closing expected by September 30, 2026; not subject to a due diligence condition
Company says the deal brings 2026 dispositions closed or under contract to about $1.5 billion, within its $1.5 to $2.0 billion full-year guidance range
Net proceeds may fund repayment of debt maturing in 2027 and repurchases under the $1.0 billion share repurchase program
Xylem said CFO William Grogan will resign effective August 31, 2026 to pursue another opportunity, and Andrea van der Berg, currently SVP Finance for the Water Infrastructure segment, will become CFO on September 1, 2026. Xylem also reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026, which matters to shareholders because it signals no change to the outlook alongside the finance leadership change.
Grogan remains employed through September 13, 2026 to support the transition.
Van der Berg's annual base salary is $675,000, with an AIP target of 80% of base salary.
Van der Berg receives a one-time 2026 LTIP award with a grant date value of $787,500, and a new LTIP target award of $1,750,000.
Xylem reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026.
GE HealthCare appointed William K. Grogan, currently executive vice president and CFO of Xylem Inc., as Chief Financial Officer effective September 14, 2026, succeeding interim CFO George Newcomb, who will remain Controller and Chief Accounting Officer. The filing sets out his pay package, including a $900,000 base salary, a 100% target bonus, and sign-on awards to offset compensation forfeited at Xylem, which matters to shareholders as it defines the company's new top finance executive and its compensation commitments.
Grogan, age 48, has been Xylem's EVP and CFO since October 2023 and was IDEX Corporation's CFO from January 2017 to September 2023.
Offer letter: $900,000 base salary, target annual bonus of 100% of salary, and a 2026 annual LTI award with a $3,300,000 target grant date value.
Sign-on payments include $550,000 in cash and a $4,000,000 RSU award, with cash repayment required if he resigns within two years.
Newcomb ceases as interim CFO on September 14, 2026, and continues as Controller and Chief Accounting Officer.
BioMarin agreed on August 17, 2026 to acquire Alesta Therapeutics, a Dutch clinical-stage biotech, for a $275 million upfront cash payment plus up to $215 million in future payments tied to development milestones. Alesta will first spin out its non-ALE1 assets, and BioMarin expects to fund the deal with cash on hand and to update its full-year 2026 guidance after closing; the company says the deal is expected to be modestly dilutive to 2026 results excluding the upfront payment.
Upfront cash payment of $275 million, subject to a customary post-closing price adjustment, plus up to $215 million in milestone-based payments
Lead asset ALE1 is an oral small molecule in a Phase 1/2a trial for hypophosphatasia, a rare genetic bone disease
Closing expected in the third quarter of 2026, subject to closing conditions; BioMarin plans to fund the deal with cash on hand
Filing states the deal is expected to be modestly dilutive to 2026 results, excluding the upfront consideration
Arxis, Inc. closed its acquisition of Omnetics Connector Corporation on August 17, 2026, based on an agreed enterprise value of $770.0 million, subject to customary closing adjustments. At closing, the company issued 13,351,964 Class A common shares, about 3.1% of total common stock as of the closing date, and funded $8.0 million of cash escrow accounts. For shareholders, the deal adds a larger share count, with the new shares subject to lockup provisions.
Closing date: August 17, 2026; Omnetics will operate within the Electronic Components segment.
Agreed enterprise value of $770.0 million, subject to customary closing adjustments; combined purchase price multiple with the MagCanica acquisition is approximately 12x FY27 estimated adjusted EBITDA.
Issued 13,351,964 Class A common shares (about 3.1% of total common stock), subject to lockup provisions; $8.0 million funded into cash escrow accounts.
Elauwit Connection reported second-quarter 2026 revenue of $2.9 million, down 46% from $5.3 million a year earlier, and a net loss of $3.1 million, compared with $0.9 million in the prior-year quarter. The company attributed the revenue decline to the timing of construction projects, which it expects to weight toward the second half of 2026, and said contracted units rose 33% year over year to 42,687.
Q2 2026 revenue was $2.9 million, down from $5.3 million in Q2 2025; six-month revenue was $7.3 million, down from $10.8 million.
Q2 2026 net loss was $3.1 million ($0.47 per share), compared with $0.9 million ($0.17 per share) a year earlier.
Contracted units reached 42,687 at June 30, 2026, up 33% year over year; billed units rose 163% to 22,967.
As of June 30, 2026, cash and cash equivalents were $1.2 million and total debt was $2.2 million.
On August 17, 2026, Cypherpunk agreed to buy mining equipment and hosting agreements from Moria Mining, LLC for $33,333,333, paid by issuing a pre-funded warrant to Winklevoss Treasury Investments, LLC (WTI) for 43,290,042 common shares. The deal adds Zcash mining capacity but also commits a large block of new shares to an affiliate of the seller, which shareholders should weigh against the expanded operations.
Purchase price is $33,333,333 for Z15 Pro mining machines with about 4.2 GSol/s of hashpower and related hosting agreements.
Payment is a pre-funded warrant for 43,290,042 shares at an exercise price of $0.001 per share; the company says this reflects a $0.77 per share common stock price.
Warrant exercise is capped at 19.99% beneficial ownership; the company will seek stockholder approval at its next annual meeting for issuance above 5,377,442 shares.
WTI, an affiliate of the seller, owns 19.9% of the company's stock and has appointed William McEvoy and Khing Oei to the board.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.